Supplement 1 Journal of Gastrointestinal and Liver Diseases - Vol
Total Page:16
File Type:pdf, Size:1020Kb
Societatea Română de Gastroenterologie şi Hepatologie (SRGH) Societatea Română de Endoscopie Digestivă (SRED) Romanian Socity of Gastroenterology and Hepatology (SRGH) Romanian Society of Digestive Endoscopy (SRED), AL XXXIII LEA CONGRES NAŢIONAL DE GASTROENTEROLOGIE, HEPATOLOGIE ŞI ENDOSCOPIE DIGESTIVĂ The XXXIII’rd National Congress Of Gastroenterology, Hepatology And Digestive Endoscopy Rezumate / Abstracts România - Timişoara, 12 - 15 Iunie 2013 România - Timişoara, 12 -15 June 2013 Journal of Gastrointestinal and Liver Diseases Official Journal of the Romanian Societies of Gastroenterology Romanian Society of Gastroenterology and Hepatology (SRGH), Romanian Society of Digestive Endoscopy (SRED), Romanian Association for the Study of the Liver (ARSF), Romanian Society of Neurogastroenterology (SRNG) Editorial Office 3rd Medical Clinic Str. Croitorilor no. 19-21 400162 Cluj-Napoca, Romania Tel./Fax: +40-264-433335 e-mail: [email protected] http: //www.jgld.ro Editor in Chief Monica Acalovschi Assistant Editors Dan L. Dumitraşcu Brînduşa Diaconu English language Editor: Sally Wood-Lamont Biostatistical Consultant: Teodora Mocan International Editorial Board Fernando Azpiroz (Barcelona, Spain) Chris J.J. Mulder (Amsterdam, NL) Daniel Dhumeaux (Creteil, France) Manuela G. Neuman (Toronto, Canada) Petr Dite (Brno, Czech Republic) Piero Portincasa (Bari, Italy) Douglas A. Drossman (Chapel Hill,NC,USA) Chris Probert (Bristol, UK) Peter Ferenci (Vienna, Austria) Claudio Puoti (Rome, Italy) Jean-Paul Galmiche (Nantes, France) Eamonn M.M. Quigley (Houston, TX, USA) Colin Howden (Chicago, IL, USA) Vlad Ratziu (Paris, France) John R. Lake (Minneapolis, MN, USA) Michael Sackmann (Bamberg, Germany) Frank Lammert (Homburg/Saar, Germany) David Sanders (Sheffield, UK) Grigorios Leontiadis (Hamilton, ON, Canada) Husain A. Saleh (Detroit, MI, USA) Peter Malfertheiner (Magdeburg, Germany) Eugene R. Schiff (Miami, FL, USA) Rui Tato Marinho (Lisbon, Portugal) Manfred Singer (Mannheim, Germany) Francesco Marotta (Milan, Italy) Guido N.J. Tytgat (Amsterdam, NL) John F. Mayberry (Leicester, UK) Radu Tutuian (Zurich, Switzerland) Romanian Editorial Board Vasile Andreica (Cluj-Napoca) Irinel Popescu (Bucharest) Radu I. Badea (Cluj-Napoca) Paul Jurgen Porr (Sibiu) Mircea Diculescu (Bucharest) Adrian Saftoiu (Craiova) Cristian Gheorghe (Bucharest) Ioan Sporea (Timişoara) Liana Gheorghe (Bucharest) Carol Stanciu (Iaşi) Adrian Goldis (Timisoara) Eugen Târcovean (Iaşi) Mircea Grigorescu (Cluj-Napoca) Anca Trifan (Iasi) Oliviu Pascu (Cluj-Napoca) Mihai Voiculescu (Bucharest) Abstracts. Supplement 1 Journal of Gastrointestinal and Liver Diseases - vol. 22 June/2013 3 ORAL PRESENTATION Journal of Gastrointestinal and Liver Diseases Genetic tests with prognostic relevance in hepatology Official Journal of the Romanian Societies of Gastroenterology Romanian Society of Gastroenterology and Hepatology (SRGH), Romanian Society of Digestive Endoscopy (SRED), OP1. IL-28B POLYMORPHISM IS A multivariate analysis IL-28B CC genotypes and sta- Romanian Association for the Study of the Liver (ARSF), Romanian Society of Neurogastroenterology (SRNG) PREDICTIVE FACTOR FOR SUSTAINED ges of fibrosis were independent predictors of SVR. VIRoloGIC RESPONSE, INSUliN Conclusions. Apart from the predictive role of SVR RESISTANCE AND HEPATIC STEATOSIS in patients with CHC treated with PegIFN plus RBV IN CHRONIC HEPATITIS C INFECTION double therapy, IL-28B CC genotype was associated Editorial Office with the degree of IR and hepatic steatosis. In our 3rd Medical Clinic Str. Croitorilor no. 19-21 Corina Radu*, Mircea Dan Grigorescu*, Dana study, IR does not undermine the advantage of IL- 400162 Cluj-Napoca, Romania Crişan, Dana Damian, Paula Szanto, Alina Habic, 28B polymorphism. Tel./Fax: +40-264-433335 Mircea Grigorescu * Equal contribution to this study. e-mail: [email protected] http: //www.jgld.ro UMF “Iuliu Hațieganu” Cluj-Napoca, Regional Institute of Gastroenterology and Hepatology Editor in Chief OP2. CoULD INTERFEROn-gamma- “Prof. Dr. O Fodor” Cluj-Napoca Monica Acalovschi INDUCTiblE PROTEIN 10 (IP-10) LEVEL BE A SUBSTITUTE FOR IL-28B OR ARE Assistant Editors Background. Sustained virologic response (SVR) THEY ADDITIVE METHODS IN ORDER Dan L. Dumitraşcu in patients with chronic hepatitis C (CHC) depends Brînduşa Diaconu TO PREDICT HEPATITIS C TREATMENT on several factors. One of the most investigated was RESPONSE? English language Editor: Sally Wood-Lamont single nucleotide polymorphism (SNP) of IL-28B gene (rs12979860) important even in the new era of Biostatistical Consultant: Teodora Mocan the triple therapy. Objectives. The aim of the study Dana Crişan*, Mircea Dan Grigorescu*, Corina was to evaluate the role of IL-28B polymorphism on Radu, Alina Habic, Adriana Cavaşi, SVR, and the association of these polymorphisms Mircea Grigorescu International Editorial Board with insulin resistance (IR) and hepatic steatosis in *first two authors equally contributed to this study Fernando Azpiroz (Barcelona, Spain) Chris J.J. Mulder (Amsterdam, NL) naive patients with CHC treated with peginterferon Daniel Dhumeaux (Creteil, France) Manuela G. Neuman (Toronto, Canada) plus ribavirin (Peg IFN and RBV). Methods. 103 Background: The serum levels of IP-10 and sin- Petr Dite (Brno, Czech Republic) Piero Portincasa (Bari, Italy) non-diabetic CHC patients with liver biopsy proven gle nucleotide polymorphysms (SNPs) of IL28B Douglas A. Drossman (Chapel Hill,NC,USA) Chris Probert (Bristol, UK) CHC genotype 1 were studied. The SNPs rs12979860 (rs12979860) are two factors that predict sustained Peter Ferenci (Vienna, Austria) Claudio Puoti (Rome, Italy) Jean-Paul Galmiche (Nantes, France) Eamonn M.M. Quigley (Houston, TX, USA) (IL-28B) were investigated by RT-PCR. Insulin re- virologic response (SVR) in patients with chronic Colin Howden (Chicago, IL, USA) Vlad Ratziu (Paris, France) sistance (HOMA-IR) stages of fibrosis and degre- hepatitis C (CHC) treated with pegylated interferon John R. Lake (Minneapolis, MN, USA) Michael Sackmann (Bamberg, Germany) es of steatosis were also evaluated. SVR and rate of and ribavirin. Frank Lammert (Homburg/Saar, Germany) David Sanders (Sheffield, UK) relapse were assessed for each polymorphism of IL- Objectives: The study was undertaken in order to Grigorios Leontiadis (Hamilton, ON, Canada) Husain A. Saleh (Detroit, MI, USA) 28B. Results. According to IL-28B polymorphisms evaluate the role of each of the above mentioned pre- Peter Malfertheiner (Magdeburg, Germany) Eugene R. Schiff (Miami, FL, USA) Rui Tato Marinho (Lisbon, Portugal) Manfred Singer (Mannheim, Germany) SVR was obtained as follows: 89.6% for genotype dictors and if the combination could improve their Francesco Marotta (Milan, Italy) Guido N.J. Tytgat (Amsterdam, NL) CC, 55.7% for genotype CT and 23.0% for genotype predictive value. John F. Mayberry (Leicester, UK) Radu Tutuian (Zurich, Switzerland) TT. The rates of relapse were 10.3%, 44.3%, 76.9% Patients and method: One hundred and two pa- for before mentioned genotypes. IR was lower in CC tients with liver biopsy proven CHC genotype 1 were genotype (1.81±0.88) compare to CT(3.7±2.75) and studied. The levels of IP-10 were assessed by ELISA Romanian Editorial Board TT genotypes(4.2±2.78), p<0.0001. T allele carriers method and the SNPs rs12979860 (IL28B) were in- Vasile Andreica (Cluj-Napoca) Irinel Popescu (Bucharest) had a higher frequency of IR irrespective of stages of vestigated by RT-PCR. Insulin resistance (HOMA- Radu I. Badea (Cluj-Napoca) Paul Jurgen Porr (Sibiu) fibrosis. Viral load at baseline was higher in CC ge- IR), stages of fibrosis, degrees of steatosis and SVR Mircea Diculescu (Bucharest) Adrian Saftoiu (Craiova) notypes then in CT or TT genotypes. Cholesterol le- were assessed for each group. Cristian Gheorghe (Bucharest) Ioan Sporea (Timişoara) vels in IL-28B CC genotype were higher (265.2±57.6 Results: For IP-10, a cut-off value of ≤ 392 pg/ Liana Gheorghe (Bucharest) Carol Stanciu (Iaşi) Adrian Goldis (Timisoara) Eugen Târcovean (Iaşi) mg%) than in genotypes CT(187.1±43.5mg%) or TT ml was obtained in order to discriminate between Mircea Grigorescu (Cluj-Napoca) Anca Trifan (Iasi) (210±57.4 mg%), p<0.005, and degree of steatosis was responders and non-responders. SVR was obtained Oliviu Pascu (Cluj-Napoca) Mihai Voiculescu (Bucharest) lower in patients with CC genotype (p=0.015). In in 63/102(61.8 %) patients with IP-10<392pg/ml vs. 4 Abstracts. Supplement 1 Journal of Gastrointestinal and Liver Diseases - vol. 22 June/2013 39/102(38.2 %) in patients with IP-10 levels >392 pg/ beginning of antiviral therapy and a mean time since ml. The AUROC was 0.768 with a sensitivity, specifi- LT of 15.1±10.9 months. Distribution of recipients city, positive predictive value (PPV) and negative pre- IL28B genotypes were: C/C -4 patients (10.5%), C/T dictive value (NPV) of 86.6%, 66.1%, 75.6%, respec- -19 patients (50%), T/T -15 patients (39.5%). Donors tively 80.4%. According to IL28B polymorphism, we IL28B genotypes were available in 16 recipients: C/C found a SVR of 89.6% for genotype CC, 55.7% for -5 patients (31.2%), C/T -9 patients (56.2%), T/T -2 genotype CT and 23.0% for genotype TT with an patients (12.6%). Early virologic response (EVR) was AUROC of 0.721 with a sensitivity, specificity, po- obtained in 75% of patients, but SVR in only 34.6%. sitive predictive value (PPV) and negative predictive Both EVR and SVR were not associated with recipi- value (NPV) of 41.27%, 92.31%, 89.76%, respectively ents IL28B genotype non-T/T (p=0.18 and p=0.97). 49.3%. The combination of IP-10 and IL28B gives an Aminotransferases were significantly higher in ge- AUROC of 0.830 with a sensitivity, specificity, PPV notype T/T patients compared to C/T and C/C pa- and NPV of 85.7%, 69.21%, 81.8%, and 75.0%, re- tients: AST =286.7±87.4 vs. 129±15.4IU/L (p=0.01) spectively. and ALT=325.5±84.4 vs. 131.5±22.1IU/L (p=0.006). Conclusion: The combination of IP-10 levels Although not statistically significant, baseline viral with IL28B genotypes improves the predictive value load, necroinflammation score ≥2 and fibrosis stage for hepatitis C treatment response.